Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review
{{output}}
Background: Lebrikizumab is a monoclonal antibody targeting interleukin 13 (IL-13), a key cytokine in the pathogenesis of atopic dermatitis (AD). It was approved by the Food and Drug Administration (FDA) in 2024 for the treatment... ...
